NO20053341L - Hindring og behandling av Alzheimers sykdom. - Google Patents

Hindring og behandling av Alzheimers sykdom.

Info

Publication number
NO20053341L
NO20053341L NO20053341A NO20053341A NO20053341L NO 20053341 L NO20053341 L NO 20053341L NO 20053341 A NO20053341 A NO 20053341A NO 20053341 A NO20053341 A NO 20053341A NO 20053341 L NO20053341 L NO 20053341L
Authority
NO
Norway
Prior art keywords
alzheimer
disease
prevention
inhibitor
treatment
Prior art date
Application number
NO20053341A
Other languages
English (en)
Norwegian (no)
Other versions
NO20053341D0 (no
Inventor
Hubert Heuer
Laurent Pradier
Hans-Ludwig Schaefer
Thierry Canton
Jesus Benavides
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20053341D0 publication Critical patent/NO20053341D0/no
Publication of NO20053341L publication Critical patent/NO20053341L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
NO20053341A 2002-12-12 2005-07-08 Hindring og behandling av Alzheimers sykdom. NO20053341L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0215722A FR2848452B1 (fr) 2002-12-12 2002-12-12 Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
PCT/FR2003/003654 WO2004062652A1 (fr) 2002-12-12 2003-12-10 Application et traitement de la maladie d'alzheimer

Publications (2)

Publication Number Publication Date
NO20053341D0 NO20053341D0 (no) 2005-07-08
NO20053341L true NO20053341L (no) 2005-09-07

Family

ID=32338722

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053341A NO20053341L (no) 2002-12-12 2005-07-08 Hindring og behandling av Alzheimers sykdom.

Country Status (22)

Country Link
EP (1) EP1572174A1 (enExample)
JP (1) JP2006514063A (enExample)
KR (1) KR20050084250A (enExample)
CN (1) CN1726016A (enExample)
AR (1) AR042354A1 (enExample)
AU (1) AU2003296802A1 (enExample)
BR (1) BR0317280A (enExample)
CA (1) CA2507945A1 (enExample)
CO (1) CO5700712A2 (enExample)
FR (1) FR2848452B1 (enExample)
HR (1) HRP20050534A2 (enExample)
MA (1) MA27500A1 (enExample)
MX (1) MXPA05005556A (enExample)
NO (1) NO20053341L (enExample)
NZ (1) NZ540496A (enExample)
PE (1) PE20040770A1 (enExample)
PL (1) PL377110A1 (enExample)
RS (1) RS20050420A (enExample)
RU (1) RU2005121909A (enExample)
TW (1) TW200503707A (enExample)
WO (1) WO2004062652A1 (enExample)
ZA (1) ZA200504656B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
ZA200603165B (en) 2003-11-03 2007-07-25 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
CN1918131B (zh) 2004-02-05 2011-05-04 前体生物药物股份公司 谷氨酰胺酰基环化酶抑制剂
CA2589102C (en) 2004-11-02 2013-08-13 Northwestern University Pyridazine compounds and methods for using the compounds to treat inflammatory diseases
EP2015750A2 (en) 2006-04-28 2009-01-21 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
PL2157973T3 (pl) * 2007-05-22 2015-12-31 Otsuka Pharma Co Ltd Lek zawierający pochodną karbostyrylu i donepezil do leczenia choroby Alzheimera
AU2012328453B2 (en) * 2011-10-28 2017-05-04 Shire Human Genetic Therapies, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
ES2633766T3 (es) * 2011-10-28 2017-09-25 Lumena Pharmaceuticals Llc Inhibidores de reciclaje de ácido biliar para el tratamiento de enfermedades de hígado colestático pediátrico

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2040996A1 (en) * 1990-05-02 1991-11-03 Robert L. Albright Composition and method for controlling cholesterol
AU668682B2 (en) * 1991-02-22 1996-05-16 Howard K. Shapiro Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
EP0910351A1 (en) * 1996-06-27 1999-04-28 G.D. Searle & Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
US5985936A (en) * 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
NZ505761A (en) * 1998-01-28 2003-08-29 Warner Lambert Co Method for treating alzheimer's disease using plasma-triglceride level-lowering agents or agents that interfer with cholesterol ester synthesis
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
DE19825804C2 (de) * 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
WO2001056579A1 (en) * 2000-02-04 2001-08-09 Esperion Therapeutics Inc. Methods for treating alzheimer's disease
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents

Also Published As

Publication number Publication date
CA2507945A1 (fr) 2004-07-29
AU2003296802A1 (en) 2004-08-10
PE20040770A1 (es) 2004-12-10
NZ540496A (en) 2008-04-30
RU2005121909A (ru) 2006-01-20
WO2004062652A1 (fr) 2004-07-29
FR2848452A1 (fr) 2004-06-18
KR20050084250A (ko) 2005-08-26
TW200503707A (en) 2005-02-01
MXPA05005556A (es) 2005-07-26
AR042354A1 (es) 2005-06-15
BR0317280A (pt) 2005-11-08
RS20050420A (sr) 2007-04-10
HRP20050534A2 (en) 2006-11-30
MA27500A1 (fr) 2005-08-01
EP1572174A1 (fr) 2005-09-14
JP2006514063A (ja) 2006-04-27
ZA200504656B (en) 2006-08-30
PL377110A1 (pl) 2006-01-23
CO5700712A2 (es) 2006-11-30
FR2848452B1 (fr) 2007-04-06
NO20053341D0 (no) 2005-07-08
CN1726016A (zh) 2006-01-25

Similar Documents

Publication Publication Date Title
PT1509232E (pt) Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer
NO20052760D0 (no) Fremgangsmate for behandling av kreft og beslektede fremgangsmater.
NO20044195L (no) Biofosfoninsyrer for behandling og prevensjon av osteoprose
GB0223040D0 (en) Therapeutic compounds
NO20034590L (no) Fremgangsmåter for behandling av vaskul¶r sykdom
NO20034549D0 (no) Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
NO20050607L (no) Fremgangsmate og innretning for tildeling av CO
CY2014028I1 (el) Ενωσεις, φαρμακοτεχνικες μορφες και μεθοδοι θεραπειας ή αποτροπhς ροδοχρωμης ακμης
AU2003230838A1 (en) Methods of diagnosing potential for metastasis or developing hepatocellular carcinoma and of identifying therapeutic targets
DK1487541T3 (da) Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelse af perifere vaskulære sygdomme
NO20084362L (no) Difenylazetidinon derivater inneholdende kolesterol absorbsjonsinhibitor aktivitet
EA200500098A1 (ru) Лекарственное средство и способ лечения патологического синдрома
NO20053341L (no) Hindring og behandling av Alzheimers sykdom.
MXPA05009986A (es) Tratamiento de la enfermedad de alzheimer.
WO2009027703A3 (en) Identifying organ damage
TW200635900A (en) Chemical compound and its use
NO20051664L (no) Behandling av demens og Parkinsons sykdom
AU2003205174A1 (en) Molecules for disease detection and treatment
WO2004028456A3 (en) Method and composition for treating neurodegenerative disorders
ATE404519T1 (de) Hyperforinderivate, ihre verwendung sowie diese enthaltende zubereitungen
IS7558A (is) Blanda af NMDA mótlyfi og asetýlkólín esterasa hindrum fyrir meðhöndlun á Alzheimers-sjúkdómnum
NO20054020D0 (no) Medisin for forhindring og behandling av arterosklerose og hypertensjon
AU2003289889A1 (en) Methods for the treatment of alzheimers disease and compositions therefore
WO2006020852A3 (en) Pharmaceutical composition and method for treating neurodegenerative disorders

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application